PTEN (phospho-S380/T382/T383) polyclonal antibody

As human tumors progress to advanced stages, one genetic alteration that occurs at high frequency is a loss of heterozygosity (LOH) at chromosome 10q23. Mapping of homozygous deletions on this chromosome led to the isolation of the PTEN gene, also designated MMAC1 (for mutated in multiple advanced cancers) and TEP1. This candidate tumor suppressor gene exhibits a high frequency of mutations in human glioblastomas and is also mutated in other cancers, including sporadic brain, breast, kidney and prostate cancers. PTEN has been associated with Cowden disease, an autosomal dominant cancer predisposition syndrome. The PTEN gene product is a putative protein tyrosine phosphatase that is localized to the cytoplasm, and it shares extensive homology with the cytoskeletal proteins tensin and auxilin. Gene transfer studies have indicated that the phosphatase domain of PTEN is essential for growth suppression of glioma cells.

Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; Mutated in multiple advanced cancers 1; Phosphatase and tensin homolog; PTEN; MMAC1; TEP1

Phosphoinosotode Signaling, PI3K AKT signaling, Translational Contral elF4 and p70 S6 Kinase, Regulation of Microtubule Dynamics, Inhibition of Apoptosis, Insulin &Glucose Signaling, MTOR signaling

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Western blot (WB) analysis of PTEN (p-S380/T382/T383) polyclonal antibody at 1:1000 dillution Lane1:Hela whole cell lysate (30μg) Lane2:Hela treated with PMA (60ng/ml, 30min) whole cell lysate (30μg) Lane3:H9C2 whole cell lysate (30μg) Lane4:H9C2 treated with PMA (60ng/ml, 30min) whole cell lysate (30μg)